Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced ...

Study analyzed global patterns and trends in ovarian cancer incidence from 1988 to 2017, highlighting variations by ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...

Epithelial ovarian cancer is the most common type of ovarian cancer. Primary peritoneal cancer and fallopian tube cancer are similar to epithelial ovarian cancer and are treated in the same way. Germ ...

A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the ...

The KEYLYNK-001 study evaluating Merck's Keytruda plus chemotherapy followed by maintenance with Lynparza meets the primary ...

Implementing an individualized starting dose (ISD) of niraparib (Zejula; GSK) reduced severe hematologic adverse event (AE) ...

Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over recent decades, improvements have been made in treatment outcome in terms of response rate and survival.

Merck has announced that the Phase 3 KEYLYNK-001 trial demonstrated that KEYTRUDA® (pembrolizumab) combined with chemotherapy ...

Merck announces phase 3 KEYLYNK-001 trial meets primary endpoint of PFS in patients with advanced epithelial ovarian cancer: Rahway, New Jersey Tuesday, December 10, 2024, 18:00 H ...

Despite marijuana remaining a Schedule I drug on the federal level, 2024 has been a huge year for marijuana research. As ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYLYNK-001 trial ...